CTAP - CAS 103429-32-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C51H69N13O11S2
Molecular Weight:
1104.32
COA:
Inquire
Targets:
Opioid Receptor
Description:
CTAP has been found to be a selective μ-opioid receptor antagonist.
Sequence:
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr
Purity:
≥95% by HPLC
Appearance:
White Solid
Synonyms:
D-Phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-arginyl-L-threonyl-3-mercapto-L-valyl-L-threoninamide cyclic (2→7)-disulfide
MSDS:
Inquire
InChIKey:
OFMQLVRLOGHAJI-FGHAYEPSSA-N
InChI:
InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1
Canonical SMILES:
CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O
1.[Opioid μ receptors mediate the stress-induced spatial reference memory impairment].
Cao LQ;Wen J;Liu ZQ Sheng Li Xue Bao. 2015 Apr 25;67(2):173-80.
Learning/memory impairment is one of the most serious problems induced by stress, and the underlying mechanisms remain unclear. Opiates and opioid receptors are implicated in multiple physiological functions including learning and memory. However, there is no clear evidence whether the endogenous opioid system is involved in the formation of the stress-induced spatial reference memory impairment. The aim of the present study was to evaluate the role of μ opioid receptor in the stress-induced spatial reference memory impairment by means of Morris water maze (MWM) test in a mouse elevated platform stress model. The mice were trained in the MWM for four trials a session for 4 consecutive days after receiving the elevated platform stress, and intracerebroventricular injection of μ opioid receptor agonist DAMGO, antagonist CTAP or saline. Retention of the spatial training was assessed 24 h after the last training session with a 60-s free-swim probe trial using a new starting position. The results showed that intracerebroventricular injection of μ opioid receptor agonist DAMGO but not antagonist CTAP before MWM training impaired the memory retrieval of mice. Elevated platform stress before MWM training also impaired memory retrieval, which could be reversed by pre-injection of CTAP, and aggravated by DAMGO.
2.G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.
Onali P;Olianas MC Br J Pharmacol. 2004 Nov;143(5):638-48. Epub 2004 Sep 27.
1 Naloxone benzoylhydrazone (NalBzoH) has initially been developed as an agonist of the pharmacologically defined kappa3-opioid receptor and has recently been employed as an antagonist at the opioid receptor-like (ORL1) receptor. In the present study, we investigated the ability of NalBzoH to elicit agonist-like effects on receptor signalling in distinct layers of rat olfactory bulb, a brain region where we have demonstrated the presence of opioid and ORL1 receptors coupled to both stimulation and inhibition of cyclic AMP formation. 2 In membranes of the olfactory nerve-glomerular layer (ON-GL), external plexiform layer (EPL) and granule cell layer (GRL), NalBzoH elicited a concentration-dependent stimulation of guanosine-5'-O-(3-[35S]-thio)triphosphate ([35S]GTPgammaS) binding with pEC50 values ranging from 7.36 to 7.86, whereas the kappa1-opioid receptor agonists (-)-U-50,488 and U-69,593 were inactive. 3 In membranes of GRL, but not ON-GL and EPL, NalBzoH stimulated basal adenylyl cyclase activity by 40% with a pEC50 of 8.14, and significantly potentiated the net enzyme stimulation elicited by corticotropin-releasing hormone and pituitary adenylate cyclase-activating peptide 38. Pertussis toxin prevented the NalBzoH stimulations of [35S]GTPgammaS binding and adenylyl cyclase activity.
3.Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes.
Wang X;Douglas SD;Peng JS;Metzger DS;O'Brien CP;Zhang T;Ho WZ J Leukoc Biol. 2006 Jun;79(6):1166-72. Epub 2006 Mar 30.
Acute and chronic alcohol abuse impairs various functions of the immune system and thus, has been implicated as a cofactor in the immunopathogenesis of human immunodeficiency virus (HIV) disease progression. We determined whether naltrexone, an opioid receptor antagonist widely used in the treatment of alcoholism, inhibits alcohol-mediated enhancement of HIV infection of T cells. Alcohol enhanced HIV infection of peripheral blood lymphocytes (PBL) and a human lymphoid cell line (CEMX174). Alcohol increased HIV X4 envelope (Env), not murine leukemia virus Env-pseudotyped infection of CEMX174 cells. Naltrexone antagonized the enhancing effect of alcohol on HIV infection of PBL and CEMX174 cells. The specific mu-opioid receptor antagonist, Cys2, Tyr3, Arg5, Pen7 (CTAP) amide, also blocked the enhancing effect of alcohol on HIV infection. Investigation of the underlying mechanism for the alcohol action showed that alcohol significantly increased endogenous beta-endorphin production and induced mu-opioid receptor mRNA expression in PBL and CEMX174 cells. The role of beta-endorphin in alcohol-mediated enhancement of HIV infection was indicated by the observations that naltrexone and CTAP antagonized ether alcohol- or exogenous beta-endorphin-mediated enhancement of HIV infection.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Opioid Receptor Products


CAS 34140-59-5 Trimebutine Maleate

Trimebutine Maleate
(CAS: 34140-59-5)

Trimebutine is an opioid receptor agonist used as spasmolytic agent abdominal pain.

CAS 1217628-73-3 SB 205607 dihydrobromide

SB 205607 dihydrobromide
(CAS: 1217628-73-3)

SB 205607 dihydrobromide is the first described non-peptide δ1 opioid receptor agonist with high affinity and selectivity for the δ1 subtype (Ki = 1.12, 2320 an...

CAS 64963-01-5 [D-Ala2]-Leucine enkephalin

[D-Ala2]-Leucine enkephalin
(CAS: 64963-01-5)

[D-Ala2]-Leucine enkephalin is a delta opioid agonist used to study the signaling pathway of delta opioid receptors.

CAS 103429-32-9 CTAP

CTAP
(CAS: 103429-32-9)

CTAP has been found to be a selective μ-opioid receptor antagonist.

CAS 188119-47-3 NocII

NocII
(CAS: 188119-47-3)

NocII, a heptadecapeptide whose sequence lies immediately downstream of nociceptin, stimulates locomotion in mice, possibly through a novel specific receptor.

CAS 16676-29-2 Naltrexone HCl

Naltrexone HCl
(CAS: 16676-29-2)

Naltrexone significantly suppresses ethanol self-administration and prevents ethanol-induced increases in dialysate dopamine levels.

CAS 114528-81-3 (+)-U-50488 hydrochloride

(+)-U-50488 hydrochloride
(CAS: 114528-81-3)

(+)-U-50488 hydrochloride is the less active enantiomer of (±)-U-50488, which is an opioid receptor agonist.

CAS 178249-42-8 Nociceptin (1-7)

Nociceptin (1-7)
(CAS: 178249-42-8)

Nociceptin (1-7), the N-terminal fragment of Nociceptin, antagonizes nociceptin-induced hyperalgesia, with no effect on nociceptin-induced analgesia.

Chemical Structure

CAS 103429-32-9 CTAP

Quick Inquiry

Verification code

Featured Items